EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Efficacy of azathioprine as a first-line therapy in new onset of acute Vogt-Koyanagi-Harada disease in the Indian population

Swapnil M Parchand, Tripti Saraogi, Samrat Chatterjee, Anil Gangwe, Deepanshu Agrawal, Deepshikha Agrawal

Saudi Journal of Ophthalmology · 2025-01 · 39 (1) · 65-70

DOI: 10.4103/sjopt.sjopt_200_23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Saudi Journal of Ophthalmology, online erschienen am 21.02.2025. Verfasst von Swapnil M Parchand und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Uvea Services, MGM Eye Institute, Raipur, Chhattisgarh, India. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The purpose of this study is to evaluate the efficacy of azathioprine as a first-line therapy in new onset of acute Vogt-Koyanagi-Harada (VKH) disease in the Indian population. METHODS: This retrospective study included 17 (34 eyes) patients who received azathioprine along with systemic steroids for new onset of acute VKH disease and had minimum follow-up of 24 months. Uveitis activity was assessed clinically and by indocyanine green angiography. RESULTS: The mean follow-up period was 27.53 (range: 24–48) months. Corticosteroid-sparing effect was achieved in 14 (82.35%) patients. The median time to achieve the steroid-sparing effect was 3 months (range: 1.5–5 months). Corrected distance visual acuity better than 0.3 logMAR was achieved in 28 (82.35%) eyes. Sunset glow fundus developed in 2 (5.88%) eyes while on azathioprine therapy. None of the eyes developed chronic granulomatous uveitis phase or severe systemic side effect during treatment with azathioprine. CONCLUSION: Azathioprine as first-line therapy in patients with new onset of acute VKH disease has effective steroid-sparing effect and prevents progression to chronic recurrent granulomatous stage.

Schlagwörter

Stichwörter der Autor:innen

AzathioprineVogt-Koyanagi-Harada diseasecorticosteroidssteroids

Autor:innen und Institutionen

  • Department of Uvea Services, MGM Eye Institute, Raipur, Chhattisgarh, India.

Zitieren

APA

Parchand, S. M., Saraogi, T., Chatterjee, S., Gangwe, A., Agrawal, D., & Agrawal, D. (2025). Efficacy of azathioprine as a first-line therapy in new onset of acute Vogt-Koyanagi-Harada disease in the Indian population. Saudi Journal of Ophthalmology, 39(1), 65-70. https://doi.org/10.4103/sjopt.sjopt_200_23

Vancouver

Parchand SM, Saraogi T, Chatterjee S, Gangwe A, Agrawal D, Agrawal D. Efficacy of azathioprine as a first-line therapy in new onset of acute Vogt-Koyanagi-Harada disease in the Indian population. Saudi Journal of Ophthalmology. 2025;39(1):65-70. doi:10.4103/sjopt.sjopt_200_23

BibTeX
@article{Parchand2025,
  author = {Parchand, Swapnil M and Saraogi, Tripti and Chatterjee, Samrat and Gangwe, Anil and Agrawal, Deepanshu and Agrawal, Deepshikha},
  title = {Efficacy of azathioprine as a first-line therapy in new onset of acute Vogt-Koyanagi-Harada disease in the Indian population},
  journal = {Saudi Journal of Ophthalmology},
  year = {2025},
  volume = {39},
  number = {1},
  pages = {65--70},
  doi = {10.4103/sjopt.sjopt_200_23}
}
Kostenlos starten →